Mantle cell lymphoma: The promise of new treatment options
- 31 October 2011
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 80 (1), 69-86
- https://doi.org/10.1016/j.critrevonc.2010.09.003
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphomaBlood, 2010
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapyBlood, 2009
- Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionProceedings of the National Academy of Sciences, 2009
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment GroupCancer, 2008
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaLeukemia & Lymphoma, 2008
- Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cellsBlood, 2007
- Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphomaCancer Chemotherapy and Pharmacology, 2007
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006